Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...

The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

Notable candidates like GamTBvac (a subunit vaccine) and viral vector-based MVATG18598 show promise in enhancing immune responses and shortening treatment regimens. Artificial intelligence (AI) and ...

Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. | Despite recent ...

Job cuts in Cambridge and Plainville are the second workforce reduction planned for the facilities in the past three months.

Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche's Luxturna and Novartis' Zolgensma.

Tax advantages offered by PEA-PME and PEA are only available to French residents. *Shares of European companies with fewer than 5,000 employees and an annual revenue of less than €1.5 billion or total ...

The virus that causes eastern equine encephalitis, or EEE, has evolved to infect mosquitoes. To be able to spread between ...

Oxford, UK – 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited ("Jefferies") as its Joint ...